- Tytuł:
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology November 2022 23(11):1367-1377
Czasopismo naukowe